Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Hepatitis B virus vaccination

Eng-Kiong Teo, MD
Anna SF Lok, MD
Section Editor
Rafael Esteban, MD
Deputy Editor
Jennifer Mitty, MD, MPH


There are more than two billion individuals with serological evidence of hepatitis B virus (HBV) infection worldwide [1]. Of these, 240 million are chronic carriers and approximately 686,000 hepatitis B related deaths occur annually [2-4]. Despite advances in antiviral therapy, only a minority of patients with chronic hepatitis B will have a sustained response. Thus, primary prevention by vaccination to increase herd immunity remains the main focus in controlling HBV infection.

Available hepatitis B vaccines are extremely safe and have an efficacy of >90 percent against all HBV serotypes and genotypes. Thus, HBV infection can potentially be eradicated through global vaccination. Globally, vaccine coverage based upon completion of the third dose of vaccine (HepB3) has increased from 3 percent in 1992 to 84 percent in 2015 [5-7]. However, even in countries that actively advocate universal vaccination, coverage is less than 100 percent. As an example, the vaccine coverage in Taiwan for birth cohorts from 1984 to 2010 was 88.8 to 96.9 percent [8,9].

In the United States, vaccine coverage among adults is low, and the overall prevalence of hepatitis B vaccine-induced immunity was 25 percent during the period from 2007 to 2012 [10]. In 2010, vaccine coverage ranged from 58 percent for those between 18 and 20 years old to 26 percent for those between 41 and 49 years old [11]. In high-risk adults, vaccine coverage for those between 19 and 49 years was 42 percent, while the coverage rate for low-risk adults in the same age range was 33 percent. Despite this suboptimal vaccine coverage, the incidence of acute hepatitis B has decreased by 90 percent in the United States (from 8.5/100,000 in 1990 to 0.9/100,000 in 2012) [12]. However, new infections continue to be seen, especially among young adults who use injection drugs [10]. (See "Epidemiology, transmission, and prevention of hepatitis B virus infection", section on 'Epidemiology of chronic HBV'.)

While vaccination represents the cornerstone of public health measures to eradicate HBV, 5 to 10 percent of individuals do not respond to currently available vaccines. Thus, other public health measures, including health education and infection control measures, remain important. (See "Epidemiology, transmission, and prevention of hepatitis B virus infection".)


The development of hepatitis B vaccine is considered to be one of the major achievements of modern medicine. Three different classes of hepatitis B vaccine are available based upon how they are derived (from plasma, yeast, or mammalian cells).


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2017. | This topic last updated: Aug 16, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. World Health Organization. Hepatitis B. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index1.html (Accessed on April 15, 2015).
  2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97.
  3. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30:2212.
  4. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385:117.
  5. World Health Organization. Immunization coverage. http://www.who.int/mediacentre/factsheets/fs378/en/ (Accessed on May 19, 2015).
  6. Helgi Library. http://www.helgilibrary.com/indicators/index/immunisation-hepb3-as-of-one-year-old-children (Accessed on May 19, 2015).
  7. World Health Organization. Global hepatitis report, 2017. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1 (Accessed on June 05, 2017).
  8. Centers for Disease Control, ROC (Taiwan). www.cdc.gov.tw/rwd/english (Accessed on June 05, 2017).
  9. Centers for Disease Control, Department of Health, ROC (Taiwan). 2012 annual report. (Accessed on June 05, 2017).
  10. Harris AM, Iqbal K, Schillie S, et al. Increases in Acute Hepatitis B Virus Infections - Kentucky, Tennessee, and West Virginia, 2006-2013. MMWR Morb Mortal Wkly Rep 2016; 65:47.
  11. Centers for Disease Control and Prevention (CDC). Adult vaccination coverage--United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 61:66.
  12. Centers for Disease Control. Viral hepatitis statistics and surveillance http://www.cdc.gov/hepatitis/Statistics/2012Surveillance/Table3.1.htm (Accessed on April 15, 2015).
  13. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303:833.
  14. UNICEF. Vaccine price data, HepB. https://www.unicef.org/supply/files/HepB.pdf (Accessed on June 05, 2017).
  15. Immunization financing in developing countries and the international vaccine market: Trends and issues www.who.int/immunization_delivery/new_vaccines/14.immunization_financingindevelopingcountries.pdf (Accessed on October 17, 2009).
  16. Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine 1990; 8 Suppl:S69.
  17. Centers for Disease Control and Prevention (CDC). Availability of hepatitis B vaccine that does not contain thimerosal as a preservative. MMWR Morb Mortal Wkly Rep 1999; 48:780.
  18. Young MD, Schneider DL, Zuckerman AJ, et al. Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine. Hepatology 2001; 34:372.
  19. Rendi-Wagner P, Kundi M, Stemberger H, et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 2001; 19:2055.
  20. Blatter M, Joines R, Resinger K, et al. An open, randomized, controlled study to evaluate the safety and immunogenicity of SmithKline Beecham Biologicals' combined hepatitis A/hepatitis B (Twinrix®) vaccine in adults (abstract 1629). In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco), American Society for Microbiology, Washington, DC 1999. p.394.
  21. Abraham B, Parenti D. Antibody production in response to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. J Infect Dis 2000; 182:1005.
  22. Vaccine Names and Abbreviations www.immunization-sd.org/docs/iz78.pdf (Accessed on October 22, 2009).
  23. Betancourt AA, Delgado CA, Estévez ZC, et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis 2007; 11:394.
  24. Makidon PE, Bielinska AU, Nigavekar SS, et al. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One 2008; 3:e2954.
  25. Jesus S, Soares E, Costa J, et al. Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly-ε-caprolactone based nanoparticles. Int J Pharm 2016; 504:59.
  26. Halperin SA, Ward B, Cooper C, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine 2012; 30:2556.
  27. Sablan BP, Kim DJ, Barzaga NG, et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 2012; 30:2689.
  28. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55:1.
  29. US. Preventive Services Task Force. Screening for Hepatitis B infection. Recommendation statement 2004. Agency for Healthcare Research and Quality. Rockville, MD www.ahrq.gov/clinic/uspstf/uspshepb.htm (Accessed on March 01, 2006).
  30. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661.
  31. The World Health Organziaiton. Guidelines for the prevention, care, and treatment of persons with chronic hepaititis B infection. http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf?ua=1 (Accessed on May 19, 2015).
  32. World Health Organization. Immunizations, vaccines, and biologicals. www.who.int/immunization/sage/2_IPAC_2011Aprilreport_FINAL_nov11.pdf (Accessed on May 19, 2015).
  33. Poovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers. J Infect Dis 2009; 200:33.
  34. Liang X, Bi S, Yang W, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis 2009; 200:39.
  35. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101:1348.
  36. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999; 12:351.
  37. Ni YH, Huang LM, Chang MH, et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 2007; 132:1287.
  38. Ni YH, Chang MH, Jan CF, et al. Continuing Decrease in Hepatitis B Virus Infection 30 Years After Initiation of Infant Vaccination Program in Taiwan. Clin Gastroenterol Hepatol 2016; 14:1324.
  39. Chiang CJ, Yang YW, You SL, et al. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013; 310:974.
  40. Margolis HS, Coleman PJ, Brown RE, et al. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995; 274:1201.
  41. http://www.nice.org.uk/ (Accessed on January 09, 2015).
  42. Stevens CE, Toy PT, Tong MJ, et al. Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA 1985; 253:1740.
  43. Lee C, Gong Y, Brok J, et al. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev 2006; :CD004790.
  44. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 2:1099.
  45. Wong VC, Ip HM, Reesink HW, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet 1984; 1:921.
  46. Poovorawan Y, Sanpavat S, Pongpunlert W, et al. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989; 261:3278.
  47. Lolekha S, Warachit B, Hirunyachote A, et al. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine 2002; 20:3739.
  48. Wen WH, Chang MH, Zhao LL, et al. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol 2013; 59:24.
  49. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54:1.
  50. Elam-Evans LD, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years--United States, 2013. MMWR Morb Mortal Wkly Rep 2014; 63:625.
  51. Centers for Disease Control and Prevention (CDC). Hepatitis B vaccination coverage among Asian and Pacific Islander children--United States, 1998. MMWR Morb Mortal Wkly Rep 2000; 49:616.
  52. Williams WW, Lu PJ, O'Halloran A, et al. Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014. MMWR Surveill Summ 2016; 65:1.
  53. Mast EE, Williams IT, Alter MJ, Margolis HS. Hepatitis B vaccination of adolescent and adult high-risk groups in the United States. Vaccine 1998; 16 Suppl:S27.
  54. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.
  55. Schillie S, Murphy TV, Sawyer M, et al. CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR Recomm Rep 2013; 62:1.
  56. Kher A, Samama MM. Low-molecular-weight heparins: weeks or months instead of days of treatment. Clin Appl Thromb Hemost 2001; 7:314.
  57. Horlander JC, Boyle N, Manam R, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci 1999; 318:304.
  58. Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011; 60:1709.
  59. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336:196.
  60. Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007; 147:460.
  61. Lok AS, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology 1988; 8:766.
  62. Shouval D. Hepatitis B vaccines. J Hepatol 2003; 39 Suppl 1:S70.
  63. http://www.doctissimo.fr/medicament-VACCIN-GENHEVAC-B-PASTEUR.htm (Accessed on September 18, 2015).
  64. Shaw FE Jr, Guess HA, Roets JM, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989; 7:425.
  65. Wiström J, Ahlm C, Lundberg S, et al. Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. Vaccine 1999; 17:2162.
  66. Zechowy R, Rubin LG. Effect of the time interval between the first and second doses of hepatitis B vaccine on the antibody titer achieved after the third dose. Child Hos Q 1997; 9:67.
  67. Middleman AB, Kozinetz CA, Robertson LM, et al. The effect of late doses on the achievement of seroprotection and antibody titer levels with hepatitis b immunization among adolescents. Pediatrics 2001; 107:1065.
  68. Halsey NA, Moulton LH, O'Donovan JC, et al. Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics 1999; 103:1243.
  69. Heron LG, Chant KG, Jalaludin BB. A novel hepatitis B vaccination regimen for adolescents: two doses 12 months apart. Vaccine 2002; 20:3472.
  70. Saito K. Introductory remark of Dr. Rokuzo Kobayashi's achievements. Keio J Med 2002; 51 Suppl 2:2.
  71. Hepatitis B vaccine: What you need to know. Available at: www.cdc.gov/vaccines/pubs/vis/downloads/vis-hep-b.pdf (Accessed on October 20, 2009).
  72. Hoofnagle JH. Toward universal vaccination against hepatitis B virus. N Engl J Med 1989; 321:1333.
  73. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315:209.
  74. Poland GA. Hepatitis B immunization in health care workers. Dealing with vaccine nonresponse. Am J Prev Med 1998; 15:73.
  75. Propst T, Propst A, Lhotta K, et al. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998; 32:1041.
  76. Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999; 33:356.
  77. Schillie S, Murphy TV, Fenlon N, et al. Update: Shortened Interval for Postvaccination Serologic Testing of Infants Born to Hepatitis B-Infected Mothers. MMWR Morb Mortal Wkly Rep 2015; 64:1118.
  78. Liao SS, Li RC, Li H, et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999; 17:2661.
  79. Lin HH, Wang LY, Hu CT, et al. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J Med Virol 2003; 69:471.
  80. Yuen MF, Lim WL, Chan AO, et al. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2004; 2:941.
  81. McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142:333.
  82. Zanetti AR, Mariano A, Romanò L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366:1379.
  83. Bruce MG, Bruden D, Hurlburt D, et al. Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose. J Infect Dis 2016; 214:16.
  84. Simons BC, Spradling PR, Bruden DJ, et al. A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen. J Infect Dis 2016; 214:273.
  85. Chang YC, Wang JH, Chen YS, et al. Hepatitis B virus vaccination booster does not provide additional protection in adolescents: a cross-sectional school-based study. BMC Public Health 2014; 14:991.
  86. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009; 200:1390.
  87. Wainwright RB, McMahon BJ, Bulkow LR, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989; 261:2362.
  88. West DJ, Watson B, Lichtman J, et al. Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy. Pediatr Infect Dis J 1994; 13:745.
  89. Chaves SS, Fischer G, Groeger J, et al. Persistence of long-term immunity to hepatitis B among adolescents immunized at birth. Vaccine 2012; 30:1644.
  90. Jan CF, Huang KC, Chien YC, et al. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology 2010; 51:1547.
  91. Bialek SR, Bower WA, Novak R, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 2008; 27:881.
  92. Lu CY, Ni YH, Chiang BL, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008; 197:1419.
  93. http://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html (Accessed on February 22, 2016).
  94. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000; 355:561.
  95. World Health Organizationa. Hepatitis B fact sheet 204. http://www.who.int/mediacentre/factsheets/fs204_Jul2014/en/ (Accessed on February 22, 2016).
  96. www.cdc.gov/hepatitis/HBV/HBVfaq.htm (Accessed on January 09, 2015).
  97. Ayoola EA, Johnson AO. Hepatitis B vaccine in pregnancy: immunogenicity, safety and transfer of antibodies to infants. Int J Gynaecol Obstet 1987; 25:297.
  98. Levy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal safety. Am J Perinatol 1991; 8:227.
  99. Shaw FE Jr, Graham DJ, Guess HA, et al. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. Am J Epidemiol 1988; 127:337.
  100. McMahon BJ, Helminiak C, Wainwright RB, et al. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am J Med 1992; 92:254.
  101. Niu MT, Davis DM, Ellenberg S. Recombinant hepatitis B vaccination of neonates and infants: emerging safety data from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 1996; 15:771.
  102. Ascherio A, Zhang SM, Hernán MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001; 344:327.
  103. Hall A, Kane M, Roure C, Meheus A. Multiple sclerosis and hepatitis B vaccine? Vaccine 1999; 17:2473.
  104. Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001; 344:319.
  105. Peces R, de la Torre M, Alcázar R, Urra JM. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis 1997; 29:239.
  106. Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989; 321:708.
  107. Langö-Warensjö A, Cardell K, Lindblom B. Haplotypes comprising subtypes of the DQB1*06 allele direct the antibody response after immunisation with hepatitis B surface antigen. Tissue Antigens 1998; 52:374.
  108. Noh KW, Poland GA, Murray JA. Hepatitis B vaccine nonresponse and celiac disease. Am J Gastroenterol 2003; 98:2289.
  109. Park SD, Markowitz J, Pettei M, et al. Failure to respond to hepatitis B vaccine in children with celiac disease. J Pediatr Gastroenterol Nutr 2007; 44:431.
  110. Cardell K, Akerlind B, Sällberg M, Frydén A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis 2008; 198:299.
  111. He JW, Lu Q, Zhu QR, et al. Mutations in the 'a' determinant of hepatitis B surface antigen among Chinese infants receiving active postexposure hepatitis B immunization. Vaccine 1998; 16:170.
  112. Zuckerman AJ, Harrison TJ, Oon CJ. Mutations in S region of hepatitis B virus. Lancet 1994; 343:737.
  113. Hsu HY, Chang MH, Ni YH, et al. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 1997; 26:786.
  114. Okamoto H, Yano K, Nozaki Y, et al. Mutations within the S gene of hepatitis B virus transmitted from mothers to babies immunized with hepatitis B immune globulin and vaccine. Pediatr Res 1992; 32:264.
  115. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336:325.
  116. Fortuin M, Karthigesu V, Allison L, et al. Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis 1994; 169:1374.
  117. Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27:213.
  118. Carman WF, Trautwein C, van Deursen FJ, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24:489.
  119. Hsu HY, Chang MH, Ni YH, Chen HL. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 2004; 53:1499.
  120. Kajiwara E, Tanaka Y, Ohashi T, et al. Hepatitis B caused by a hepatitis B surface antigen escape mutant. J Gastroenterol 2008; 43:243.
  121. Hsu HY, Chang MH, Ni YH, et al. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. J Infect Dis 2010; 201:1192.
  122. http://www.euro.who.int/vaccine/diseases/20090127_15 (Accessed on May 23, 2010).
  123. Announcements-Bill and Melinda Gates Foundation http://www.gatesfoundation.org/globalhealth/pri_diseases/vaccines/announcements (Accessed on January 25, 2006).
  124. Kane MA. Global status of hepatitis B immunisation. Lancet 1996; 348:696.
  125. World Health Organization. Hepatitis B. Fact sheet 204. Updated March 2015. www.who.int/mediacentre/factsheets/fs204/en/ (Accessed on May 20, 2015).
  126. http://www.gavi.org/library/news/statements/2014/Hepatitis-B-vaccine-at-birth-GAVI-responds-to-MSF/ (Accessed on May 20, 2015).
  127. Singh M, Li XM, McGee JP, et al. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine 1997; 15:475.
  128. Schödel F, Milich DR, Will H. Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination. J Immunol 1990; 145:4317.
  129. Mason HS, Lam DM, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci U S A 1992; 89:11745.
  130. Borges O, Tavares J, de Sousa A, et al. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur J Pharm Sci 2007; 32:278.
  131. Gupta PN, Khatri K, Goyal AK, et al. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J Drug Target 2007; 15:701.
  132. Thomas C, Rawat A, Bai S, Ahsan F. Feasibility study of inhaled hepatitis B vaccine formulated with tetradecylmaltoside. J Pharm Sci 2008; 97:1213.
  133. Thomas C, Gupta V, Ahsan F. Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles. Pharm Res 2010; 27:905.
  134. Rahman F, Dahmen A, Herzog-Hauff S, et al. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 2000; 31:521.
  135. Rault R, Freed B, Nespor S, Bender F. Efficacy of different hepatitis B vaccination strategies in patients receiving hemodialysis. ASAIO J 1995; 41:M717.
  136. Fabrizi F, Dixit V, Magnini M, et al. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther 2006; 24:497.
  137. Fabrizi F, Andrulli S, Bacchini G, et al. Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997; 12:1204.
  138. Quiroga JA, Carreño V. Interferon and hepatitis B vaccine in haemodialysis patients. Lancet 1989; 1:1264.
  139. Jungers P, Devillier P, Salomon H, et al. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 1994; 344:856.
  140. Thoelen S, Van Damme P, Mathei C, et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998; 16:708.
  141. Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis 1996; 174:1168.
  142. Jacques P, Moens G, Desombere I, et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 2002; 20:3644.
  143. Fabrizi F, Tarantino A, Castelnovo C, et al. Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study. Kidney Blood Press Res 2015; 40:584.
  144. Levie K, Gjorup I, Skinhøj P, Stoffel M. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults. Scand J Infect Dis 2002; 34:610.
  145. Boland G, Beran J, Lievens M, et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 2004; 23:316.
  146. Moss B, Smith GL, Gerin JL, Purcell RH. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 1984; 311:67.
  147. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745.
  148. Milich DR, Thornton GB, Neurath AR, et al. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 1985; 228:1195.
  149. Zuckerman JN, Sabin C, Craig FM, et al. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. BMJ 1997; 314:329.
  150. Suzuki H, Iino S, Shiraki K, et al. Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing. Vaccine 1994; 12:1090.
  151. Haubitz M, Ehlerding G, Beigel A, et al. Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency. Clin Nephrol 1996; 45:180.
  152. Yap I, Guan R, Chan SH. Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines. J Gastroenterol Hepatol 1995; 10:51.
  153. Shapira MY, Zeira E, Adler R, Shouval D. Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. J Hepatol 2001; 34:123.